Wars leave damage in their wake, and the war on cancer may be no exception. Radiation therapy and chemotherapy have improved survivorship, but they also may leave the cardiovascular system battle scarred.
The practice of medicine continues to be challenged by the rapid evolution of technology. That’s especially difficult when physicians lack strong evidence or must make decisions amid conflicting findings.
This is a tale of making cardiac care better. Better for patients, better for the caregivers providing it, and better for a hospital morphing and migrating to thrive in the new world of accountable care.
Digoxin has long been a mainstay in the treatment of systolic heart failure (HF). Recently, however, some studies have called its safety into question after finding the use of the drug in contemporary practice was associated with higher mortality rates.
